@targetedonc.bsky.social
#ASCO25 Recap: Immunotherapy takes center stage! Dr. David Spigel shares the key highlights. ▶️ Watch now! #CancerTreatment #SarahCannon
June 3, 2025 at 6:16 PM
#ASCO25 Recap: Immunotherapy takes center stage! Dr. David Spigel shares the key highlights. ▶️ Watch now! #CancerTreatment #SarahCannon
Follow along for real-time updates from #ASCO25 and insights from the ground floor of the world’s leading oncology conference!
www.targetedonc.com/conference/a...
#OncologyInnovation #MedicalOncology #CancerResearch #PrecisionMedicine
www.targetedonc.com/conference/a...
#OncologyInnovation #MedicalOncology #CancerResearch #PrecisionMedicine
June 2, 2025 at 3:18 PM
Follow along for real-time updates from #ASCO25 and insights from the ground floor of the world’s leading oncology conference!
www.targetedonc.com/conference/a...
#OncologyInnovation #MedicalOncology #CancerResearch #PrecisionMedicine
www.targetedonc.com/conference/a...
#OncologyInnovation #MedicalOncology #CancerResearch #PrecisionMedicine
Listening in on Dr. Yijun Shen’s presentation at #AUA25 regarding DV + BCG in #NMIBC🔊Stay tuned for more on the story at targetedonc.com/conference/aua
April 27, 2025 at 12:24 AM
Listening in on Dr. Yijun Shen’s presentation at #AUA25 regarding DV + BCG in #NMIBC🔊Stay tuned for more on the story at targetedonc.com/conference/aua
Urine Luck! Targeted Oncology is live from #AUA25, bringing you the latest breakthroughs and insights straight from the meeting floor. Stay tuned for exclusive updates!
April 26, 2025 at 3:57 PM
Urine Luck! Targeted Oncology is live from #AUA25, bringing you the latest breakthroughs and insights straight from the meeting floor. Stay tuned for exclusive updates!
In this interview, Jennifer Chan, MD, MPH, discussed the recent #FDA approval of #cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors. @danafarber.bsky.social
www.targetedonc.com/view/behind-...
www.targetedonc.com/view/behind-...
April 3, 2025 at 1:46 PM
In this interview, Jennifer Chan, MD, MPH, discussed the recent #FDA approval of #cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors. @danafarber.bsky.social
www.targetedonc.com/view/behind-...
www.targetedonc.com/view/behind-...
Take a look back on all the #FDA happenings from the month of March 2025: www.targetedonc.com/view/fda-onc...
April 2, 2025 at 5:19 PM
Take a look back on all the #FDA happenings from the month of March 2025: www.targetedonc.com/view/fda-onc...
BREAKING: The #FDA approved durvalumab (Imfinzi) plus chemotherapy followed by single-agent durvalumab for the treatment of patients with muscle-invasive bladder cancer after radical cystectomy. #blcsm
www.targetedonc.com/view/fda-gra...
www.targetedonc.com/view/fda-gra...
March 28, 2025 at 8:57 PM
BREAKING: The #FDA approved durvalumab (Imfinzi) plus chemotherapy followed by single-agent durvalumab for the treatment of patients with muscle-invasive bladder cancer after radical cystectomy. #blcsm
www.targetedonc.com/view/fda-gra...
www.targetedonc.com/view/fda-gra...
The #FDA approved cabozantinib for adult and pediatric patients aged 12+ with previously treated, unresectable, locally advanced/metastatic, well-differentiated pancreatic neuroendocrine tumors & well-differentiated extra-pancreatic neuroendocrine tumors.
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
March 26, 2025 at 2:45 PM
The #FDA approved cabozantinib for adult and pediatric patients aged 12+ with previously treated, unresectable, locally advanced/metastatic, well-differentiated pancreatic neuroendocrine tumors & well-differentiated extra-pancreatic neuroendocrine tumors.
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
By 2037, US oncologist demand (26,620) will outpace supply (24,630), with a 15% vs. 7% increase, highlighting a growing workforce shortage. @jrgralow.bsky.social @ascocancer.bsky.social
hubs.li/Q03cYJ4C0
hubs.li/Q03cYJ4C0
March 25, 2025 at 5:50 PM
By 2037, US oncologist demand (26,620) will outpace supply (24,630), with a 15% vs. 7% increase, highlighting a growing workforce shortage. @jrgralow.bsky.social @ascocancer.bsky.social
hubs.li/Q03cYJ4C0
hubs.li/Q03cYJ4C0
March is #NutritionAwarenessMonth. From prevention to survivorship, diet impacts cancer outcomes, but emerging evidence demands we rethink traditional paradigms. Learn more from Marleen I. Meyers, MD, a breast medical oncologist at NYU Langone Health: www.targetedonc.com/view/-nutrit...
March 24, 2025 at 4:35 PM
March is #NutritionAwarenessMonth. From prevention to survivorship, diet impacts cancer outcomes, but emerging evidence demands we rethink traditional paradigms. Learn more from Marleen I. Meyers, MD, a breast medical oncologist at NYU Langone Health: www.targetedonc.com/view/-nutrit...
Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated #melanoma. #melsm |
hubs.li/Q03cxRYs0
hubs.li/Q03cxRYs0
March 21, 2025 at 7:41 PM
Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated #melanoma. #melsm |
hubs.li/Q03cxRYs0
hubs.li/Q03cxRYs0
The #FDA has granted approval to TLX007-CDx for the preparation of PSMA-PET imaging for prostate cancer. #pcsm
www.targetedonc.com/view/fda-oks...
www.targetedonc.com/view/fda-oks...
March 20, 2025 at 11:30 PM
The #FDA has granted approval to TLX007-CDx for the preparation of PSMA-PET imaging for prostate cancer. #pcsm
www.targetedonc.com/view/fda-oks...
www.targetedonc.com/view/fda-oks...
March is #ColorectalCancerAwarenessMonth. Here, Scott Kopetz, MD, PhD, FACP, (@skopetz.bsky.social) discussed the BREAKWATER trial in metastatic BRAF V600E-mutated colorectal cancer. #crcsm | @mdanderson.bsky.social
hubs.li/Q039ZhBC0
hubs.li/Q039ZhBC0
March 11, 2025 at 1:12 PM
March is #ColorectalCancerAwarenessMonth. Here, Scott Kopetz, MD, PhD, FACP, (@skopetz.bsky.social) discussed the BREAKWATER trial in metastatic BRAF V600E-mutated colorectal cancer. #crcsm | @mdanderson.bsky.social
hubs.li/Q039ZhBC0
hubs.li/Q039ZhBC0
#FDA Approves Frontline Tislelizumab Plus Chemotherapy in Advanced #ESCC
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
March 5, 2025 at 7:14 PM
#FDA Approves Frontline Tislelizumab Plus Chemotherapy in Advanced #ESCC
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
Cancer research is at risk as NIH funding cuts threaten clinical trials & young investigators. Gwen Nichols, MD, shares urgent insights on the future of innovation. Sign up to read the full articles below! @llsusa.bsky.social
www.targetedonc.com/view/cancer-...
www.targetedonc.com/view/medicai...
www.targetedonc.com/view/cancer-...
www.targetedonc.com/view/medicai...
February 26, 2025 at 6:22 PM
Cancer research is at risk as NIH funding cuts threaten clinical trials & young investigators. Gwen Nichols, MD, shares urgent insights on the future of innovation. Sign up to read the full articles below! @llsusa.bsky.social
www.targetedonc.com/view/cancer-...
www.targetedonc.com/view/medicai...
www.targetedonc.com/view/cancer-...
www.targetedonc.com/view/medicai...
#ASH24 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in #CLL.
www.targetedonc.com/view/highlig...
www.targetedonc.com/view/highlig...
February 20, 2025 at 5:27 PM
#ASH24 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in #CLL.
www.targetedonc.com/view/highlig...
www.targetedonc.com/view/highlig...
Discover how molecular oncology is revolutionizing cancer diagnosis & treatment by uncovering the genetic and molecular drivers of tumor growth—going far beyond traditional methods.
Sign up now & gain insights that are reshaping oncology practice: www.targetedonc.com/view/evoluti...
Sign up now & gain insights that are reshaping oncology practice: www.targetedonc.com/view/evoluti...
January 21, 2025 at 5:13 PM
Discover how molecular oncology is revolutionizing cancer diagnosis & treatment by uncovering the genetic and molecular drivers of tumor growth—going far beyond traditional methods.
Sign up now & gain insights that are reshaping oncology practice: www.targetedonc.com/view/evoluti...
Sign up now & gain insights that are reshaping oncology practice: www.targetedonc.com/view/evoluti...
Rahul Banerjee, MD, (@rahulbanerjeemd.bsky.social) discussed approaches to dosing and tolerability when using talquetamab in patients with relapsed/refractory multiple myeloma. #mmsm | @uwmedicine.bsky.social @fredhutch.bsky.social
www.targetedonc.com/view/banerje...
www.targetedonc.com/view/banerje...
January 17, 2025 at 5:56 PM
Rahul Banerjee, MD, (@rahulbanerjeemd.bsky.social) discussed approaches to dosing and tolerability when using talquetamab in patients with relapsed/refractory multiple myeloma. #mmsm | @uwmedicine.bsky.social @fredhutch.bsky.social
www.targetedonc.com/view/banerje...
www.targetedonc.com/view/banerje...
The #FDA has approved axatilimab-csfr (Niktimvo), an anti–CSF-1R antibody, in 9 mg and 22 mg vial sizes for patients with chronic #GVHD failure of at least 2 prior lines of systemic therapy.
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
January 16, 2025 at 8:16 PM
The #FDA has approved axatilimab-csfr (Niktimvo), an anti–CSF-1R antibody, in 9 mg and 22 mg vial sizes for patients with chronic #GVHD failure of at least 2 prior lines of systemic therapy.
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
Major gynecologic cancer advances in 2024: new therapies in endometrial (T-DXd), cervical (Keytruda), and ovarian (Elahere + Avastin) cancers show potential to change practice. #gyncsm
www.targetedonc.com/view/novel-t...
www.targetedonc.com/view/novel-t...
January 7, 2025 at 7:54 PM
Major gynecologic cancer advances in 2024: new therapies in endometrial (T-DXd), cervical (Keytruda), and ovarian (Elahere + Avastin) cancers show potential to change practice. #gyncsm
www.targetedonc.com/view/novel-t...
www.targetedonc.com/view/novel-t...
🎄✨ Happy Holidays from Targeted Oncology! ✨🎄
As we wrap up another year of advancements in cancer care, we want to take a moment to thank our incredible community for their continued support in advancing cancer care. Wishing you a joyful and restful holiday season! 🌟
As we wrap up another year of advancements in cancer care, we want to take a moment to thank our incredible community for their continued support in advancing cancer care. Wishing you a joyful and restful holiday season! 🌟
December 25, 2024 at 3:52 PM
🎄✨ Happy Holidays from Targeted Oncology! ✨🎄
As we wrap up another year of advancements in cancer care, we want to take a moment to thank our incredible community for their continued support in advancing cancer care. Wishing you a joyful and restful holiday season! 🌟
As we wrap up another year of advancements in cancer care, we want to take a moment to thank our incredible community for their continued support in advancing cancer care. Wishing you a joyful and restful holiday season! 🌟
The #FDA approved ensartinib for ALK+ locally advanced or metastatic non-small cell lung cancer. #lcsm #NCSLC
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
December 19, 2024 at 6:20 PM
The #FDA approved ensartinib for ALK+ locally advanced or metastatic non-small cell lung cancer. #lcsm #NCSLC
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
We’re having a blast at #ASH24! 🎉 Stay tuned as Targeted Oncology brings you the latest breakthroughs, data, and key insights straight from the meeting. Follow along for real-time updates on the cutting-edge advancements in oncology: lnkd.in/esX4urz
December 10, 2024 at 7:26 PM
We’re having a blast at #ASH24! 🎉 Stay tuned as Targeted Oncology brings you the latest breakthroughs, data, and key insights straight from the meeting. Follow along for real-time updates on the cutting-edge advancements in oncology: lnkd.in/esX4urz
We are here at #ASH24! Follow along with our coverage at targetedonc.com 🩸🔬 #heme #hematology #ASH2024 @ash-hematology.bsky.social
December 8, 2024 at 8:37 PM
We are here at #ASH24! Follow along with our coverage at targetedonc.com 🩸🔬 #heme #hematology #ASH2024 @ash-hematology.bsky.social
ICYMI: The #FDA has granted approval to revumenib (SNDX-5613) for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia. #leusm
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
November 19, 2024 at 1:36 PM
ICYMI: The #FDA has granted approval to revumenib (SNDX-5613) for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia. #leusm
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...